Salarius Pharmaceuticals Inc Asset Acquisition Agreement with DeuteRx LLC - M&A Call Transcript
Good day and welcome to the Salarius Pharmaceuticals Oncology Pipeline Expansion conference call. (Operator Instructions) As a reminder, this call may be recorded. I would now like to turn the call over to [Jason Landa], (inaudible) Strategic Advisors (inaudible).
Good morning and thank you for joining Salarius Pharmaceuticals on today's conference call. Earlier this morning, Salarius Pharmaceuticals issued a press release detailing a cash and stock transaction with DeuteRx LLC for the acquisition of a protein degradation portfolio, which we encourage listeners to read.
The press release can be found in the news section of SalariusPharma.com. Salarius also filed an 8-K this morning, which is available on SalriusPharma.com and SEC.gov.
Before beginning the call, I would like to make the following statement, today, we'll be making certain forward looking statements about operating metrics, future expectations, plans, events and circumstances, including
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |